Clinical usefulness of transcription-mediated amplification and hybridization protection assay in imatinib-treated chronic myelogenous leukemia patients

Clinical and Laboratory Haematology

Volumn 27, Issue 6, 2005, Pages 416-417

  Sumi, M ^a   Tauchi, T ^a   Sashida, G ^a   Shoji, N ^a   Gotoh, A ^a   Itoh, Y ^a   Miyazawa, K ^a   Kimura, Y ^a   Ohyashiki, J H ^a   Ohyashiki, K ^a  

^a TOKYO MEDICAL UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

BCR ABL PROTEIN; DNA; HETERODUPLEX; IMATINIB; MESSENGER RNA; PRIMER DNA; RIBONUCLEASE; RNA; RNA POLYMERASE;

AMPLICON; BLOOD; BLOOD SAMPLING; CANCER PATIENT; CHEMOLUMINESCENCE; CHRONIC MYELOID LEUKEMIA; CYTOGENETICS; DNA HYBRIDIZATION; DNA PROBE; DNA SYNTHESIS; ENZYME ACTIVITY; GENE AMPLIFICATION; GENETIC TRANSCRIPTION; HUMAN; INTERMETHOD COMPARISON; LETTER; PRIORITY JOURNAL; PROMOTER REGION; QUANTITATIVE ANALYSIS; REVERSE TRANSCRIPTION; RNA REPLICATION; TRANSCRIPTION INITIATION;

HUMANS; LEUKEMIA, MYELOID, CHRONIC; NEOPLASM, RESIDUAL; NUCLEIC ACID AMPLIFICATION TECHNIQUES; PIPERAZINES; PYRIMIDINES; RNA, NEOPLASM;

EID: 28944446397     PISSN: 01419854     EISSN: 13652257     Source Type: Journal    
DOI: 10.1111/j.1365-2257.2005.00723.x     Document Type: Letter

References (5)

1. Faderl S., Talpaz M., Kantarjian H.M. & Estrov Z. (1999) Should polymerase chain reaction analysis to detect minimal residual disease in patients with chronic myelogenous leukemia be used in clinical decision making? Blood 93, 2755-2759.
2. Hughes T.P., Kaeda J., Branford S., Rudzki Z., Hochhaus A., Hensley M.L., Gathmann I., Bolton A.E., van Hoomissen I.C., Goldman J.M., Radich J.P., International Randomised Study of Interferon versus STI571 (IRIS) Study Group (2003) Frequency of major molecular responses to imatinib or interferon alfa plus cytarabine in newly diagnosed patients with chronic myeloid leukemia. New England Journal of Medicine 349, 1421-1430.
3. Langabeer S.E., Gale R.E., Harvey R.C., Cook R.W., Mackinnon S. & Linch D.C. (2002) Transcription-mediated amplification and hybridization protection assay to determine BCR-ABL transcript levels in patients with chronic myeloid leukemia. Leukemia 16, 393-399.
4. O'Brien S.G., Guilhot F., Larson R.A., Gathmann I., Baccarani M., Cervantes F., Cornelissen J.J., Fisher T., Hochhause A., Hughes T., Lechner K., Nielsen J.L., Rousselot P., Reiffers J., Salglio G., Shepherd J., Simonsson S., Gratwhohl A., Goldman J.M., Kantarjian H., Taylor K., Verhoef G., Bolton A.E., Capdeville R., Druker B.J., IRIS Investigators (2003) Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myelogenous leukemia. New England Journal of Medicine 348, 994-1004.
5. van der Velden V.H., Hochhaus A., Cazzaniga G., Szczepanski T., Gabert J. & van Dongen J.J. (2003) Detection of minimal residual disease in hematologic malignancies by real-time quantitative PCR: principles, approaches, and laboratory aspects. Leukemia 17, 1013-1034.